Literature DB >> 386509

Heparin: an old drug with a new paradigm.

L B Jacques.   

Abstract

Recent studies have shown that heparin is a biochemical representative of a distinct class of compounds known as linear anionic polyelectrolytes. Members of this class are mixtures of individual highly negatively charged chains that show a wide spectrum of specific reactions with biologically active proteins. Upon administration, heparin chains enter a cellular pool and effectively prevent thrombosis by increasing the electronegative potential of the vessel wall. Anticoagulant activity is an unusual feature of a few heparin chains and appears to play a minor role in many clinical uses and in physiological and pathological responses.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 386509     DOI: 10.1126/science.386509

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  19 in total

1.  Substrate masking: binding of RNA by EGTA-inactivated micrococcal nuclease results in artifactual inhibition of RNA processing reactions.

Authors:  M J Wang; P Gegenheimer
Journal:  Nucleic Acids Res       Date:  1990-11-25       Impact factor: 16.971

2.  Mapping and quantification of the major oligosaccharide components of heparin.

Authors:  R J Linhardt; K G Rice; Y S Kim; D L Lohse; H M Wang; D Loganathan
Journal:  Biochem J       Date:  1988-09-15       Impact factor: 3.857

Review 3.  Modification of atherosclerosis by agents that do not lower cholesterol.

Authors:  J G Cleland; D M Krikler
Journal:  Br Heart J       Date:  1993-01

4.  Interaction of heparin with synthetic antithrombin III peptide analogues.

Authors:  J Bae; U R Desai; A Pervin; E E Caldwell; J M Weiler; R J Linhardt
Journal:  Biochem J       Date:  1994-07-01       Impact factor: 3.857

5.  Heparin attenuates low-dose streptozotocin-induced immune diabetes in mice and inhibits the beta-cell binding of T-splenocytes in vitro.

Authors:  P Saï; S Pogu; M Ouary
Journal:  Diabetologia       Date:  1991-04       Impact factor: 10.122

6.  Mechanism of inhibition of mammalian DNA topoisomerase I by heparin.

Authors:  K Ishii; S Futaki; H Uchiyama; K Nagasawa; T Andoh
Journal:  Biochem J       Date:  1987-01-01       Impact factor: 3.857

7.  Heparin potentiates in vivo neutrophil migration induced by IL-8.

Authors:  M Dias-Baruffi; G Pereira-da-Silva; M C Jamur; M C Roque-Barreira
Journal:  Glycoconj J       Date:  1998-05       Impact factor: 2.916

8.  Inhibition of leucocyte elastase by heparin and its derivatives.

Authors:  F Redini; J M Tixier; M Petitou; J Choay; L Robert; W Hornebeck
Journal:  Biochem J       Date:  1988-06-01       Impact factor: 3.857

9.  The noncovalent bonding of antibiotics to a polytetrafluoroethylene-benzalkonium graft.

Authors:  R A Harvey; R S Greco
Journal:  Ann Surg       Date:  1981-11       Impact factor: 12.969

10.  Mast-cell products and heparin stimulate the production of mononuclear-cell factor by cultured human monocyte/macrophages.

Authors:  J R Yoffe; D J Taylor; D E Woolley
Journal:  Biochem J       Date:  1985-08-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.